Harvard Bioscience, Inc. to Participate in the Sidoti Micro Cap Conference
Harvard Bioscience (HBIO) has announced its participation in the upcoming Sidoti Micro Cap Virtual Conference on January 22nd, 2025. The company's Chairman and CEO Jim Green, along with CFO Jennifer Cote, will deliver a presentation at 10:00 am ET.
The presentation will be accessible through a live webcast via the investor relations section of Harvard Bioscience's website. Interested parties can view the presentation replay after its conclusion. One-on-one meetings can be arranged through the conference organizers.
Harvard Bioscience (HBIO) ha annunciato la sua partecipazione alla prossima Sidoti Micro Cap Virtual Conference che si terrà il 22 gennaio 2025. Il presidente e CEO dell'azienda, Jim Green, insieme al CFO Jennifer Cote, presenterà un intervento alle 10:00 ET.
La presentazione sarà accessibile tramite un webcast dal vivo nella sezione relazioni con gli investitori del sito web di Harvard Bioscience. Le parti interessate possono visualizzare la replica della presentazione dopo la sua conclusione. È possibile organizzare incontri individuali tramite gli organizzatori della conferenza.
Harvard Bioscience (HBIO) ha anunciado su participación en la próxima Sidoti Micro Cap Virtual Conference que se llevará a cabo el 22 de enero de 2025. El presidente y CEO de la empresa, Jim Green, junto con la CFO Jennifer Cote, realizará una presentación a las 10:00 am ET.
La presentación será accesible a través de una transmisión en vivo en la sección de relaciones con inversores del sitio web de Harvard Bioscience. Las partes interesadas pueden ver la repetición de la presentación después de su conclusión. Se pueden organizar reuniones uno a uno a través de los organizadores de la conferencia.
하버드 바이오사이언스(HBIO)는 2025년 1월 22일에 열리는 시도티 마이크로 캡 가상 회의에 참가한다고 발표했습니다. 회사의 회장 겸 CEO인 짐 그린과 CFO 제니퍼 코트가 오전 10시 ET에 발표를 진행할 예정입니다.
이번 발표는 하버드 바이오사이언스 웹사이트의 투자자 관계 섹션을 통해 실시간 웹캐스트로 접속할 수 있습니다. 관심 있는 사람들은 발표가 끝난 후 재생 영상을 볼 수 있습니다. 1대 1 미팅은 회의 주최 측을 통해 조율할 수 있습니다.
Harvard Bioscience (HBIO) a annoncé sa participation à la prochaine Sidoti Micro Cap Virtual Conference qui se tiendra le 22 janvier 2025. Le président et CEO de l'entreprise, Jim Green, ainsi que la CFO Jennifer Cote, donneront une présentation à 10h00 ET.
La présentation sera accessible via un webinaire en direct dans la section relations investisseurs du site web de Harvard Bioscience. Les parties intéressées pourront visionner la rediffusion de la présentation après sa conclusion. Des réunions individuelles peuvent être organisées avec les organisateurs de la conférence.
Harvard Bioscience (HBIO) hat seine Teilnahme an der bevorstehenden Sidoti Micro Cap Virtual Conference am 22. Januar 2025 bekannt gegeben. Der Vorsitzende und CEO des Unternehmens, Jim Green, wird zusammen mit CFO Jennifer Cote eine Präsentation um 10:00 Uhr ET halten.
Die Präsentation wird über einen Live-Webcast im Bereich Investor Relations der Website von Harvard Bioscience zugänglich sein. Interessierte Parteien können die Aufzeichnung der Präsentation nach ihrem Abschluss ansehen. Einzelgespräche können über die Veranstalter der Konferenz organisiert werden.
- None.
- None.
HOLLISTON, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be participating in the Sidoti Micro Cap Virtual Conference on January 22nd, 2025, with a presentation time of 10:00 am ET.
The presentation will be webcast live and can be accessed through the investor relations section of the Harvard Bioscience website: https://investor.harvardbioscience.com/events-and-presentations. A replay will be available on the company’s website shortly after the presentation has concluded.
To schedule a one-on-one meeting, please contact the conference organizers directly.
About Harvard Bioscience, Inc.
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world. For more information, please visit our website at www.harvardbioscience.com
Company Contact:
Harvard Bioscience
Jennifer Cote, Chief Financial Officer
(508) 893-3120
Investor Contacts:
Three Part Advisors
Sandy Martin / Erol Girgin
HBIO@threepa.com
(214) 616-2207
FAQ
When is Harvard Bioscience (HBIO) presenting at the Sidoti Micro Cap Conference 2025?
How can investors access HBIO's Sidoti Conference presentation?
Will there be a replay available of HBIO's Sidoti Conference presentation?
Who will represent HBIO at the Sidoti Micro Cap Conference 2025?
How can investors schedule one-on-one meetings with HBIO management at the Sidoti Conference?
